Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -1K | -2K | -355 |
| Operating Income | -2M | -3M | -4M | -4M | -2M |
| EBITDA | -2M | -3M | -4M | -4M | -2M |
| Net Income | -2M | -3M | -6M | -4M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.042
-2.33% today
1Y Change
-83.54%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PharmaTher Holdings Ltd. (PHRRF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.04 and down 83.5% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +51.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +51.3%, free cash flow +65.6% with operating margin 0.0% and ROIC -241.0%. Stock Foundry combines PHRRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHRRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHRRF Max Drawdown
-90.31%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHRRF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
$2.7M
+166.4% YoY
Free Cash Flow
$917.9K
+126.1% YoY
Revenue Growth
+0.0%
EPS Growth
+51.3%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | -1K | -2K | -355 |
| Operating Income | -2M | -3M | -4M | -4M | -2M |
| EBITDA | -2M | -3M | -4M | -4M | -2M |
| Net Income | -2M | -3M | -6M | -4M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 923K | 2M | 6M | 9M | 3M |
| Total Assets | 1M | 3M | 6M | 12M | 6M |
| Total Liabilities | 366K | 253K | 892K | 330K | 361K |
| Shareholder Equity | 974K | 2M | 5M | 12M | 6M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -923K | -2M | -6M | -9M | -3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
922K
+126.3% YoY
Capital Expenditures
4K
Free Cash Flow
918K
+126.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-155.5%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.